Cargando…
Etifoxine, a TSPO Ligand, Worsens Hepatitis C-Related Insulin Resistance but Relieves Lipid Accumulation
Etifoxine, an 18 kDa translocator protein (TSPO) agonist for the treatment of anxiety disorders in clinic, may be able to cause acute liver injury or cytolytic hepatitis. TSPO has been demonstrated to participate in inflammatory responses in infective diseases as well as to modulate glucose and lipi...
Autores principales: | Lin, Yu-Min, Sun, Hung-Yu, Chiu, Wen-Tai, Su, Hui-Chen, Chien, Yu-Chieh, Chang, Heng-Ai, Chong, Lee-Won, Chang, Hung-Chuen, Young, Kung-Chia, Bai, Chyi-Huey, Tsao, Chiung-Wen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432734/ https://www.ncbi.nlm.nih.gov/pubmed/30984779 http://dx.doi.org/10.1155/2019/3102414 |
Ejemplares similares
-
Reduction of Traumatic Brain Damage by Tspo Ligand Etifoxine
por: Shehadeh, Mona, et al.
Publicado: (2019) -
Calcitriol Inhibits HCV Infection via Blockade of Activation of PPAR and Interference with Endoplasmic Reticulum-Associated Degradation
por: Lin, Yu-Min, et al.
Publicado: (2018) -
Translocator Protein Ligand Etifoxine Attenuates MPTP-Induced Neurotoxicity
por: Tian, Qi, et al.
Publicado: (2022) -
Etifoxine for Pain Patients with Anxiety
por: Choi, Yun Mi, et al.
Publicado: (2015) -
Differential effects of the translocator protein 18 kDa (TSPO) ligand etifoxine and the benzodiazepine alprazolam on startle response to predictable threat in a NPU-threat task after acute and short-term treatment
por: Brunner, Lisa-Marie, et al.
Publicado: (2022)